The global Real-World Evidence (RWE) Solutions Market reached USD 3,191.57 million in 2025, reflecting strong growth with a CAGR of 14.27% during the forecast period. In 2025, North America dominated the market with a value of USD 1,357.14 million, supported by advanced healthcare infrastructure, high adoption of digital health technologies, and strong regulatory support for real-world data applications. RWE solutions gain traction across clinical research, drug development, and post-market surveillance, enabling evidence-based decision-making and improved patient outcomes. The market is highly competitive, with key players such as IQVIA, Parexel, Oracle Health Sciences, Evidera, and Medidata Solutions focusing on platform innovation, strategic collaborations, and expansion into emerging markets. Increasing demand for cost-effective clinical trials, regulatory compliance, and personalized medicine continues to drive the adoption of RWE solutions globally.
Real-world Evidence (RWE) Solutions overview
Published by MMR Statistics Research Team, Updated
